Evidence map›Paper›PMID 38018190›Full record

ReviewCurrent medicinal chemistry2025

Recent Updates on the Efficacy of Mitocans in Photo/Radio-therapy for Targeting Metabolism in Chemo/Radio-resistant Cancers: Nanotherapeutics.

Xiaoyan Wang, Junqi Liu, Lakshmi Durga, Narasimha M Beeraka, Runze Zhou, Pengwei Lu, Ruixia Song, Mikhail Y Sinelnikov, Kuo Chen, Ruitai Fan and 1 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Preparation of FeInternational journal of nanomedicine · 2026
    Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 5 countries.

Xiaoyan WangDepartment of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Junqi LiuDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Lakshmi DurgaDepartment of Pharmacology, JSS College of Pharmacy, JSS Academy of Higher Education & Research (JSS AHER), Mysuru, Karnataka, India.
Narasimha M BeerakaRaghavendra Institute of Pharmaceutical Education and Research (RIPER), Anantapuramu, Chiyyedu, Andhra Pradesh, 515721, India.
Runze ZhouDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Pengwei LuDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ruixia SongCancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Mikhail Y SinelnikovSinelab Biomedical Research Centre, Minnesota, 55905, USA.
Kuo ChenDepartment of Breast Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ruitai FanDepartment of Radiation Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Di ZhaoDepartment of Endocrinology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
First Affiliated Hospital of Zhengzhou University · CNJSS Academy of Higher Education and Research · INUniversity of Rome Tor Vergata · ITSechenov University · RU

Funding

China postdoctoral Science 2022M712887Henan Natural Science Foundation of China 222300420534Henan Province Science and Technology Research Project 222102310106National Natural Science Foundation of China 81700729
6 · The paper itself

Abstract

Conventional therapeutic modalities against the cancers such as surgery, chemotherapy (CT) and radiotherapy (RT) have limited efficacy due to drug resistance, and adverse effects. Recent developments in nanoscience emphasized novel approaches to overcome the aforementioned limitations and subsequently improve overall clinical outcomes in cancer patients. Photodynamic therapy (PDT), photothermal therapy (PTT), and radiodynamic therapy (RDT) can be used as cancer treatments due to their high selectivity, low drug resistance, and low toxicity. Mitocans are the therapeutic molecules that can produce anti-cancer effects by modulating mitochondria functions and they have significant implications in cancer therapy. Mitochondria- targeted therapy is a promising strategy in cancer treatment as these organelles play a crucial function in the regulation of apoptosis and metabolism in tumor cells and are more vulnerable to hyperthermia and oxidative damage. The aim of this review is used to explore the targeting efficacy of mitocans in the nanotherapeutic formulation when combined with therapies like PDT, PTT, RDT. We searched several databases include Pubmed, relemed, scopus, google scholar, Embase and collected the related information to the efficacy of mitocans in nanotherapeutics when combined with photo-radiotherapy to target chemo/radio-resisant tumor cells. In this review, we vividly described research reports pertinent to the selective delivery of chemotherapy molecules into specific sub-organelles which can significantly improve the efficiency of cancer treatment by targeting tumor cell metabolism. Furthermore, the rational design, functionalization and application of various mitochondrial targeting units, including organic phosphine/sulfur salts, quaternary ammonium salts, transition metal complexes, and mitochondria-targeted cancer therapy such as PDT, PTT, RDT, and others were summarized. Mainly, the efficacy of these modalities against mtDNA and additional nanotherapeutic strategies with photosensitizers, or radiotherapy to target mitochondrial metabolism in tumor cells with chemo/radio-resistance were delineated. This review can benefit nanotechnologists, oncologists, and radiation oncologists to develop rational designs and application of novel mitochondrial targeting drugs mainly to target metabolism in chemo/radio-resistant cancer cells in cancer therapy.

Indexed as

Antineoplastic AgentsNeoplasmsOrganophosphorus CompoundsAnimalsDrug Resistance, NeoplasmHumansMitochondriaNanoparticlesPhotochemotherapyAntineoplastic AgentsOrganophosphorus CompoundsCancer stem cellschemistrychemo/ radio-resistance.mitocansnanosystemsphotosensitizersuncouplers

Identifiers

PMID38018190
OpenAlexW4389148884

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.